Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 2, March-April, p. 231–236

doi: 10.17219/acem/64875

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

A comparative study of sTREM-1, IL-6 and IL-13 concentration in bronchoalveolar lavage fluid in asthma and COPD: A preliminary study

Małgorzata Proboszcz1,A,D, Magdalena Paplińska-Goryca1,C,D,E,F, Patrycja Nejman-Gryz1,B, Katarzyna Górska1,B, Rafał Krenke1,D,E,F

1 Department of Internal Medicine, Medical University of Warsaw, Poland


Background. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is a cell-surface receptor presented on neutrophils, macrophages and monocytes. Elevated sTREM-1 levels are a marker of acute microbial infections, and have also been reported in chronic lung diseases. IL-6 and IL-13 are effective markers in distinguishing these diseases. IL-6 has been shown to play an important role in chronic obstructive pulmonary disease (COPD), while IL-13 is described as one of the key mediators of allergic asthma.
Objectives. The aim of the study was to evaluate the level of sTREM-1 in bronchoalveolar lavage fluid (BALF) from stable mild-to-moderate asthma and COPD patients and to compare the utility of BALF sTREM-1 measurements in asthma/COPD differentiation with those of IL-6 and IL-13.
Material and Methods. The concentration of sTREM-1, IL-6 and IL-13 was evaluated by ELISA in the BALF of stable mild-to-moderate asthma and COPD patients.
Results. There were no significant differences in BALF sTREM-1 levels between asthma and COPD patients (52.5 pg/mL for asthma vs 73.4 pg/mL for COPD, p = 0.492), in contrast to the differences in the IL6/IL13 ratio (0.68 in COPD, 0.22 in asthma, p = 0.043).
Conclusion. The study showed that BALF sTREM-1 levels do not discriminate between mild-to-moderate asthma and COPD. In contrast, the IL-6/IL-13 ratio measured in BALF effectively differentiated these two diseases in their stable state. These results suggest that the most important marker of inflammation in mild-to-moderate obstructive lung disease is not microbiology-dependent.

Key words

IL-6, asthma, COPD, IL-13, sTREM-1

References (30)

  1. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006;7:1266–1273.
  2. Read CB, Kuijper JL, Hjorth SA, et al. Cutting edge: Identification of neutrophil PGLYRP1 as a ligand for TREM-1. J Immunol. 2015;194: 1417–1421.
  3. Bleharski JR, Kiessler V, Buonsanti C, et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the ear-ly-induced and adaptive phases of the immune response. J Immunol. 2003;170:3812–3818.
  4. Radsak MP, Salih HR, Rammensee HG, Schild H. Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: Differential regulation of activation and survival. J Immunol. 2004;172:4956–63.
  5. Gibot S, Cravoisy A, Kolopp-Sarda MN, et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med. 2005;33:792–796.
  6. Masekela R, Anderson R, de Boeck K, et al. Expression of soluble triggering receptor expressed on myeloid cells-1 in childhood CF and non-CF bronchiectasis. Pediatr Pulmonol. 2015;50:333–339.
  7. Gómez-Piña V, Soares-Schanoski A, Rodríguez-Rojas A, et al. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccha-ride-stimulated human monocytes. J Immunol. 2007;179:4065–4073.
  8. Mahdy AM, Lowes DA, Galley HF, Bruce JE, Webster NR. Production of soluble triggering receptor expressed on myeloid cells by lipopoly-saccharide-stimulated human neutrophils involves de novo protein synthesis. Clin Vaccine Immunol. 2006;13:492–495.
  9. Lemarié J, Barraud D, Gibot S. Host response biomarkers in sepsis: Overview on sTREM-1 detection. Methods Mol Biol. 2015;1237:225–239.
  10. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004;350:451–458.
  11. Rohde G, Radsak MP, Borg I, Buhl R, Schultze-Werninghaus G, Taube C. Levels of soluble triggering receptor expressed on myeloid cells 1 in infectious exacerbations of chronic obstructive pulmonary disease. Respiration. 2012;83:133–139.
  12. Bucova M, Suchankova M, Dzurilla M, et al. Inflammatory marker sTREM-1 reflects the clinical stage and respiratory tract obstruction in aller-gic asthma bronchiale patients and correlates with number of neutrophils. Mediators Inflamm. 2012;2012:628754.
  13. Park JJ, Cheon JH, Kim BY, et al. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig Dis Sci. 2009;54:1525–1531.
  14. Yasuda T, Takeyama Y, Ueda T, et al. Increased levels of soluble triggering receptor expressed on myeloid cells-1 in patients with acute pancreatitis. Crit Care Med. 2008;36:2048–2053.
  15. Röpcke S, Holz O, Lauer G, et al. Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PloS One. 2012;7:e46207.
  16. Ravi AK, Khurana S, Lemon J, et al. Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. Respir Res. 2014;15:103.
  17. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–120.
  18. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: Central mediator of allergic asthma. Science. 1998;282:2258–2261.
  19. Grubek-Jaworska H, Paplińska M, Hermanowicz-Salamon J, et al. IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests. Respiration. 2012;84:101–7.
  20. Radsak MP, Taube C, Haselmayer P, et al. Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol. 2007; 2007:52040.
  21. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2010 update. Accessed Feb­ruary 12 2016.
  22. Global Initiative for Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pul-monary disease. 2010 update. Accessed February 12 2016.
  23. Meyer KC, Raghu G, Baughman RP. An official American Thoracic Society clinical practice guideline: The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185:1004–1014.
  24. Phua J, Koay ESC, Zhang D, et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur Respir J. 2006;28:695–702.
  25. ten Oever J, Tromp M, Bleeker-Rovers CP, et al. Combination of biomarkers for the discrimination between bacterial and viral lower respir-atory tract infections. J Infect. 2012;65:490–495.
  26. Shu CC, Lee LN, Wu MF, et al. Use of soluble triggering receptor expressed on myeloid cells-1 in non-tuberculous mycobacterial lung dis-ease. Int J Tuberc Lung Dis. 2011;15:1415–1420.
  27. Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease. Thorax. 2012;67:456–463.
  28. Suau A, Bonnet R, Sutren M, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol. 1999;65: 4799–4807.
  29. Donaldson GC, Seemungal TAR, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995–2004.
  30. Komai-Koma M, McKay A, Thomson L, et al. Immuno-regulatory cytokines in asthma: IL-15 and IL-13 in induced sputum. Clin Exp Allergy. 2001;31:1441–1448.